As of November 8, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. The largest reported stake is Faraday Future Intelligent Electric Inc.'s, at 19.99%. 5 filings are on record since August 7, 2025 (Schedule 13D/A, November 19, 2025).
Who owns FF EAI Robotics Ecosystem Inc.?
Sell to companies like ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Alpha Capital Anstalt · Percent: 0.51% · SCHEDULE 13G/A
- · Holder: Faraday Future Intelligent Electric Inc. · Percent: 19.99% · SCHEDULE 13D/A
- · Holder: Alpha Capital Anstalt · Percent: 9.06% · SCHEDULE 13G/A
- · Holder: Faraday Future Intelligent Electric Inc. · Percent: 8% · SCHEDULE 13D
- · Holder: Alpha Capital Anstalt · Percent: 2.22% · SCHEDULE 13G/A
ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. has 5 Schedule 13D or 13G filings on record since 2025-08-07. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Faraday Future Intelligent Electric Inc. | 19.99% | 1,227,147 | SCHEDULE 13D/A, 2025-11-19 | 2025-11-17 |
| Alpha Capital Anstalt | 0.51% | 36,003 | SCHEDULE 13G/A, 2026-01-29 | 2026-01-28 |
Holding shares or following this stake? See who's behind ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. and the warning signs.
Free to see. No signup.
Keep reading
More on ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. and the records around it.
ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. elsewhere on the record
- Acquisition Oct 2026
- Leadership changes Oct 2026
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Alpha Capital Anstalt also filed stake reports on 7 other companies: FABRIC.AI, INC. (Aug 2026), LogicMark, Inc. (May 2026), CYABRA, INC. (Mar 2026)
Watch ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.
Get an email when ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Faraday Future Intelligent Electric Inc.
The Reporting Person is filing this First Amendment to report that it has acquired beneficial ownership of shares of Common Stock issuable upon the conversion of shares of Series B Preferred Stock that were purchased pursuant to the Subscription Agreement but which were not convertible until the receipt of the approval of the Issuer's stockholders, which approval was obtained on November 12, 2025, as reported on the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 17, 2025. The Reporting Person may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Person also entered into a Lead Investor Agreement with the Issuer on September 19, 2025, pursuant to which the Issuer agreed to appoint members of its board of directors and certain officers designated by the Reporting Person upon the closing of the transactions contemplated by the Subscription Agreement (the "Lead Investor Agreement"). A copy of the Lead Investor Agreement was filed with the Original Schedule 13D as Exhibit 2. The Reporting Person intends to review its investment in the Issuer on a continuing basis and may decide at any time to increase the size of its investment in the Issuer in the open market, in …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-19; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Alpha Capital Anstalt | 2.22% | SCHEDULE 13G/A |
| 2025-11-12 | Alpha Capital Anstalt | 9.06% | SCHEDULE 13G/A |
| 2025-11-12 | Faraday Future Intelligent Electric Inc. | 8% | SCHEDULE 13D |
| 2025-11-19 | Faraday Future Intelligent Electric Inc. | 19.99% | SCHEDULE 13D/A |
| 2026-01-29 | Alpha Capital Anstalt | 0.51% | SCHEDULE 13G/A |
Questions about who owns ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.
Who owns ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.?
On this page, one holder's latest ownership filing reports 5% or more of ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.: Faraday Future Intelligent Electric Inc. (19.99%, Schedule 13D/A, filed 2025-11-19).
When did Faraday Future Intelligent Electric Inc. buy into ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.?
The filings give report dates, not purchase dates. The earliest filing from Faraday Future Intelligent Electric Inc. on this page is the Schedule 13D, filed 2025-11-12, reporting 8%; its latest, Schedule 13D/A filed 2025-11-19, reports 19.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 26, 2026 | Leadership change: Yueting Jia appointed, Chief Executive Officer | — | Leadership changes | Source |
| October 23, 2026 | Acquired RobotCo | — | Acquisition | Source |
| May 28, 2026 | Leadership change: Koti Meka departs, Chief Financial Officer, and 3 more | — | Leadership changes | Source |
| August 13, 2025 | Form D, private offering | $4.50M sold | Form D page | Source |
| November 22, 2024 | Form D, private offering | $5.10M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.